Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD)

Launched by ASSIUT UNIVERSITY · Sep 24, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a specific protein called soluble CD25 (sCD25) in patients with systemic sclerosis (SSc), a disease that affects the skin and internal organs. The researchers want to understand how the levels of this protein relate to how active the disease is, especially in patients who may or may not also have interstitial lung disease (ILD), a condition that affects the lungs. This study aims to gather important information that could help in managing and treating these patients.

To participate in this trial, individuals must be adults over 18 years old who have been diagnosed with SSc according to specific criteria. However, people with other autoimmune diseases or those whose ILD is caused by something other than SSc won't be able to join. Participants will have their sCD25 levels measured and monitored throughout the study, helping researchers learn more about the relationship between this protein and the disease's activity. This could lead to better understanding and treatment options for those living with systemic sclerosis.

Gender

ALL

Eligibility criteria

• 1. Inclusion criteria:
• • SSc patients fulfilled the 2013 ACR/EU LAR criteria (10). Adult age above 18 years.
• 2. Exclusion criteria:
• • Patients unwilling to participate in the study.
• • Patients with other autoimmune diseases.
• • Patients with interstitial lung disease (ILD) caused by causes other than systemic sclerosis.